STOCK TITAN

BIMI International Medical Inc - BIMI STOCK NEWS

Welcome to our dedicated news page for BIMI International Medical (Ticker: BIMI), a resource for investors and traders seeking the latest updates and insights on BIMI International Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIMI International Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIMI International Medical's position in the market.

Rhea-AI Summary
BIMI Holdings Inc. (NASDAQ: BIMI) received a delinquency compliance alert notice from Nasdaq due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Nasdaq granted the Company 60 days to submit a plan to regain compliance with the Rule. The Company plans to submit its compliance plan by June 18, 2024, potentially extending the deadline to October 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
BIMI Holdings Inc. (NASDAQ: BIMI) announced the results of the 2022 Annual General Meeting of Stockholders, including the election of directors, changes to bylaws and certificate of incorporation, and ratification of the appointment of Enrome LLP as the independent registered public accounting firm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
none
-
Rhea-AI Summary
BIMI International Medical Inc. (BIMI) announced its financial results for the three months and nine months ended September 30, 2023, reporting a decrease in revenues compared to the previous year. The net loss for the three months ended September 30, 2023, increased compared to the same period in 2022. Despite positive working capital, the company experienced a decline in cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.75%
Tags
News
Rhea-AI Summary
BIMI International Medical Inc. (BIMI) announced the buyback of 7,066,913 warrants at $0.30 per share, totaling $2,120,073.80. The warrants will be cancelled upon receipt of the purchase price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.97%
Tags
buyback
-
Rhea-AI Summary
BIMI International Medical Inc. (BIMI) reported a significant increase in gross margin and revenues for the six months ended June 30, 2023, compared to the same period in 2022. The acquisition of Phenix Bio Inc. contributed to the revenue growth, with the company achieving a gross margin of 52%. The cash position and working capital also improved, with positive working capital of $6,604,643 as of June 30, 2023. Mr. Tiewei Song, the CEO, expressed satisfaction with the success achieved by Phenix Bio Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.57%
Tags
-
Rhea-AI Summary
BIMI International Medical Inc. (BIMI) received a notification letter from Nasdaq stating non-compliance with filing requirements. The letter allows a maximum of 180 days for BIMI to file delinquent reports and regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.57%
Tags
none
Rhea-AI Summary
BIMI - Phenix Bio Inc. Launches CUCA 3.0 Product Line on China Duty Free Group's Online Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
Rhea-AI Summary
BIMI International Medical Inc. announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd. as its exclusive distributor for Phenix's 17 herbal supplements in Hong Kong, Taiwan, and Macau. Hao Mu must make annual purchases of at least $5 million to maintain its exclusive distributor status. This partnership aims to make top-tier herbal supplements accessible to individuals in these territories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
management
-
Rhea-AI Summary
BIMI International Medical Inc. announces the appointment of Hao Mu Pte. Ltd. as a distributor for Phenix Bio Inc.'s 17 herbal supplements in Mainland China. Hao Mu must make annual purchases of at least $5 million to maintain its distributor status. This partnership allows Phenix's high-quality herbal supplements to reach consumers in Mainland China through Hao Mu's distribution channels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
management
Rhea-AI Summary
BIMI International Medical Inc. appoints Hao Mu Pte. Ltd. as exclusive distributor for Phenix Bio Inc.'s herbal supplements in ASEAN countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
management
BIMI International Medical Inc

Nasdaq:BIMI

BIMI Rankings

BIMI Stock Data

22.27M
2.77M
76.62%
0.1%
0.12%
Iron and Steel Forging
Manufacturing
Link
China (Mainland)
Shenyang

About BIMI

bimi international medical inc. (nasdaq: bimi) is an american multinational healthcare products and services provider, offering a broad range of healthcare products and related services. the company currently operates in four segments: wholesale pharmaceuticals, wholesale medical devices, medical services and retail pharmacy. the wholesale pharmaceuticals segment includes supplying prescription and otc medicines, traditional chinese medicines (“tcm”), healthcare supplies and sundry items to clinics, third party pharmacies, hospitals and other drug wholesalers. the wholesale medical devices segment distributes medical devices, including medical consumables to private clinics, hospitals, third party pharmacies and other medical device dealers. medical services include private comprehensive hospitals operating in china. the retail pharmacy segment sells prescription and otc medicines, tcm, healthcare supplies and sundry items to retail customers through its directly-owned pharmacies a